Daily Derm Times: March 24, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

CBD products are popular in skincare, but their dermatologic benefits and safety require further evaluation.
Emrosi, a low-dose oral minocycline for rosacea, is now available following FDA approval.
ESK-001, a TYK2 inhibitor, shows sustained psoriasis improvement over 52 weeks in phase 2 trials.
Elevated eosinophil levels may serve as a marker for chronic urticaria in pediatric patients.
Delgocitinib demonstrates long-term safety and efficacy for chronic hand eczema, reducing pain and itch.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Do CBD Products Belong in Therapeutic Dermatology?

CBD skin care is booming, but are patients getting real benefits? Learn about CBD legality, safety, and potential dermatologic effects.

Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea

The lowest-dose oral minocycline for rosacea is now available by prescription following FDA approval in November 2024.

Celebrating the "Derm Difference": Mona Gohara, MD, on the Impact of National Dermatologist Day

As a featured clinician in EltaMD’s Derm Day campaign, Mona Gohara, MD, spoke about her connection with the brand and the work being done to unify dermatologists and promote skin health.

ESK-001: A Conversation with Jörn Drappa, MD, PhD, of Alumis on Breakthrough Data and the Future of Psoriasis Treatment

At the 2025 AAD Annual Meeting, Alumis Inc. presented promising phase 2 STRIDE trial results for ESK-001, a TYK2 inhibitor showing sustained psoriasis improvements over 52 weeks.

New Study Reveals Risk Factors for Persistent Urticaria

Researchers have identified elevated eosinophil levels as a potential marker for chronic urticaria in pediatric patients.

DELTA 3 Showcases Long-Term Safety and Efficacy of Delgocitinib for Chronic Hand Eczema

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.